ArticleClinical research in cardiology supplements2015
Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.
Article in Clinical research in cardiology supplements, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- The relationship between Lp(a) and CVD outcomes: a systematic review.Lipids in health and disease · 2016Pooled it
- Associations of lipoprotein(a) concentrations with cardiovascular disease in men and women with primary hypercholesterolemia.Atherosclerosis plus · 2026Article
- Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis.European cardiology · 2026Review
- Association Between Lipoprotein(a) and Dilatation of Different Aortic Segments in Hypertensive Patients.Echocardiography (Mount Kisco, N.Y.) · 2025Article
- Atherosclerosis and Its Related Laboratory Biomarkers.International journal of molecular sciences · 2023Review
- Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.Molecules (Basel, Switzerland) · 2023Review
- Familial Hyperlipidemia Caused by Apolipoprotein B Mutation in the Pediatric Amish Population: A Mini Review.Interventional cardiology · 2023Article
- Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages.Frontiers in cardiovascular medicine · 2023Article
- Synthesis, Molecular Docking, and Preclinical Evaluation of a New Succinimide Derivative for Cardioprotective, Hepatoprotective and Lipid-Lowering Effects.Molecules (Basel, Switzerland) · 2022Article
- Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B.BMC cardiovascular disorders · 2022Article
- Article
- Lipid and Haematologic Profiling of Regular Blood Donors Revealed Health Benefits.Journal of blood medicine · 2022Article
- Moxibustion for treating patients with hyperlipidemia: A systematic review and meta-analysis protocol.Medicine · 2019Article
- Observational
- Reverse Cholesterol Transport: Molecular Mechanisms and the Non-medical Approach to Enhance HDL Cholesterol.Frontiers in physiology · 2018Review
- Effect of 405 nm low intensity irradiation on the absorption spectrum of in-vitro hyperlipidemia blood.Technology and health care : official journal of the European Society for Engineering and Medicine · 2018Article
- Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.Clinical research in cardiology supplements · 2017Article
- Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.Oxidative medicine and cellular longevity · 2017Review
- Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.Blood transfusion = Trasfusione del sangue · 2016Review
- Phosphocholine-containing ligands direct CRP induction of M2 macrophage polarization independent of T cell polarization: Implication for chronic inflammatory states.Immunity, inflammation and disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein (a) [Lp(a)] is a modified LDL particle with an additional apolipoprotein [apo(a)] protein covalently attached by a thioester bond. Multiple isoforms of apo(a) exist that are genetically determined by differences in the number of Kringle-IV type-2 repeats encoded by the LPA gene. Elevated plasma Lp(a) is an independent risk factor for cardiovascular disease.The phenotypic diversity of familial Lp(a) hyperlipidemia [Lp(a)-HLP] and familial hypercholesterolemia [FH], as defined risks with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revision of the current diagnostic and therapeutic recommendations established for isolated familial Lp(a)-HLP or FH in combination with elevated Lp(a) levels.Lp(a) assays still suffer from poor standardization, comparability and particle variation. Further evaluation of the current biomarkers and establishment of novel comorbidity biomarkers are necessary for extended risk assessment of cardiovascular disease in FH or Lp(a)-HLP and to better understand the pathophysiology and to improve patient stratification of the Lp(a) syndrome complex.Lp(a) promotes vascular remodeling, increased lesion progression and intima media thickening through induction of M1-macrophages, antiangiogenic effects (e.g. vasa vasorum) with secretion of the antiangiogenic chemokine CXCL10 (IP10) and CXCR3 mediated activation of Th1- and NK-cells.In addition inhibition of serine proteases causing disturbances of thrombosis/ hemostasis/ fibrinolysis, TGFb-activation and acute phase response (e.g. CRP, anti-PL antibodies) are major features of Lp(a) pathology. Anti-PL antibodies (EO6 epitope) also bind to oxidized Lp(a).Lipoprotein apheresis is used to reduce circulating lipoproteins in patients with severe FH and/or Lp(a)-HLP, particularly with multiple cardiovascular risks who are intolerant or insufficiently responsive to lipid-lowering drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.